TY - JOUR
T1 - Toxicity of FED chemotherapy in non-small-cell lung cancer
AU - Sridhar, K. S.
AU - Varki, J.
AU - Donnelly, E.
AU - Davila, E.
AU - Benedetto, P.
AU - Hilsenbeck, S.
AU - Thurer, R. J.
AU - Rao, R. K.
AU - Fountzilas, G.
AU - Beattie, E. J.
PY - 1987/1/1
Y1 - 1987/1/1
N2 - Twenty-eight patients with metastatic and/or recurrent non-small-cell lung cancer were treated with a new sequential combination of escalating doses of cisplatin (50, 75, and 100 mg/m2 IV x 1) followed by 5-FU infusion (40 mg/m2/hour x 72) and etoposide (80 mg/m2/day x 3). Three patients received concurrent external radiation therapy. Eleven of the 28 (39%) had a partial response to chemotherapy. Four others had a minor response. One partial responder became a complete responder by surgical excision of residual cancer. Median time to response was 6 weeks followed by a median response duration of 4 months. In responders, chemotherapy was discontinued at the time of maximal response. Median survival was 7 months. Chemotherapy was well tolerated with absence of leucopenia, thrombocytopenia, and nausea and vomiting in a majority of courses. The common toxicities were alopecia (100%), leucopenia (35%), nausea and vomiting (30%), and electrolyte imbalances (27%). Reversible nephrotoxicity, thrombocytopenia, anemia, mucositis, and diarrhea were infrequent. The response rate in stage IV was less than in stage III. The combination of moderate doses of cisplatin, 5-FU infusion, and etoposide provides a new palliative chemotherapy that is well tolerated with concurrent/sequential radiation therapy and may be useful in the multimodality treatment of non-small-cell lung cancer.
AB - Twenty-eight patients with metastatic and/or recurrent non-small-cell lung cancer were treated with a new sequential combination of escalating doses of cisplatin (50, 75, and 100 mg/m2 IV x 1) followed by 5-FU infusion (40 mg/m2/hour x 72) and etoposide (80 mg/m2/day x 3). Three patients received concurrent external radiation therapy. Eleven of the 28 (39%) had a partial response to chemotherapy. Four others had a minor response. One partial responder became a complete responder by surgical excision of residual cancer. Median time to response was 6 weeks followed by a median response duration of 4 months. In responders, chemotherapy was discontinued at the time of maximal response. Median survival was 7 months. Chemotherapy was well tolerated with absence of leucopenia, thrombocytopenia, and nausea and vomiting in a majority of courses. The common toxicities were alopecia (100%), leucopenia (35%), nausea and vomiting (30%), and electrolyte imbalances (27%). Reversible nephrotoxicity, thrombocytopenia, anemia, mucositis, and diarrhea were infrequent. The response rate in stage IV was less than in stage III. The combination of moderate doses of cisplatin, 5-FU infusion, and etoposide provides a new palliative chemotherapy that is well tolerated with concurrent/sequential radiation therapy and may be useful in the multimodality treatment of non-small-cell lung cancer.
UR - http://www.scopus.com/inward/record.url?scp=0023514277&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023514277&partnerID=8YFLogxK
U2 - 10.1097/00000421-198712000-00008
DO - 10.1097/00000421-198712000-00008
M3 - Article
C2 - 2446489
AN - SCOPUS:0023514277
VL - 10
SP - 499
EP - 506
JO - American Journal of Clinical Oncology
JF - American Journal of Clinical Oncology
SN - 0277-3732
IS - 6
ER -